SCHEMBL10162873

SCHEMBL10162873

Cn1c(=O)oc2ccc(CNC(=O)c3cc(C(=O)NCc4ccccc4)n4nccc4n3)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 3/20 0.44
LMNA P02545 3/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MMP13 P45452 2/20 0.42
HSD17B10 Q99714 2/20 0.41
METTL3 Q86U44 1/20 0.41
METTL14 Q9HCE5 1/20 0.41
THRB P10828 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8227479 0.93 MEN1 (0.44) TP53MAPTPOLBMEN1KMT2A
SCHEMBL8225360 0.93 LMNA (0.41) TP53ALDH1A1KDM4EHPGDLMNA
SCHEMBL10162840 0.93 L3MBTL1 (0.48) TP53ALDH1A1KDM4EHPGDLMNA
SCHEMBL8229567 0.92 ROCK2 (0.42) TP53POLBMMP13METTL3ADAMTS4
SCHEMBL10162848 0.92 POLB (0.48) TP53ALDH1A1KDM4EHPGDLMNA
SCHEMBL8225302 0.92 HPGD (0.40) TP53ALDH1A1KDM4EHPGDLMNA
SCHEMBL8225958 0.92 TP53 (0.44) TP53LMNASMN1; SMN2MAPTPOLB
SCHEMBL8225381 0.91 HPGD (0.49) TP53ALDH1A1KDM4EHPGDGAA
SCHEMBL8228682 0.91 MMP13 (0.47) ALDH1A1KDM4EHPGDLMNASMN1; SMN2
SCHEMBL10162862 0.91 TP53 (0.40) TP53ALDH1A1KDM4EHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 TP53 3627/4885ALDH1A1 1806/4885KDM4E 2058/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 TP53 3627/4885ALDH1A1 1806/4885KDM4E 2058/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 TP53 3627/4885ALDH1A1 1806/4885KDM4E 2058/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 TP53 3627/4885ALDH1A1 1806/4885KDM4E 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.